European Journal of Obstetrics & Gynecology and Reproductive Biology
Volume 96, Issue 2 , Pages 196-201 , June 2001

Plasma levels of free vascular endothelial growth factor165 (VEGF165) are not elevated during gonadotropin stimulation in in vitro fertilization (IVF) patients developing ovarian hyperstimulation syndrome (OHSS): results of a prospective cohort study with matched controls

  • Anders Enskog

      Affiliations

    • Department of Obstetrics and Gynecology, Sahlgrenska University Hospital, Goteborg University, 413 45 Goteborg, Sweden
    • Department of Anesthesiology and Intensive care, Sahlgrenska University Hospital, Goteborg University, 413 45 Goteborg, Sweden
    • Corresponding Author InformationCorresponding author. Tel.: +46-31-21-000; fax: +46-31-82-92-48
    • ,
  • Lars Nilsson

      Affiliations

    • Department of Obstetrics and Gynecology, Sahlgrenska University Hospital, Goteborg University, 413 45 Goteborg, Sweden
    • ,
  • Mats Brännström

      Affiliations

    • Department of Obstetrics and Gynecology, Sahlgrenska University Hospital, Goteborg University, 413 45 Goteborg, Sweden

Received 20 March 2000 ,Revised 4 May 2000 ,Accepted 14 July 2000.

References 

  1. Agrawal R, Chimusoro K, Payne N, Spuy Z, Jacobs H. Severe ovarian hyperstimulation syndrome: serum and ascitic fluid concentrations of vascular endothelial growth factor. Curr. Opin. Obstet. Gynecol. 1997;9:141–144
  2. Agrawal R, Tan SL, Wild S, Sladkevicius P, Engmann L, Payne N, et al. Serum vascular endothelial growth factor concentrations in in vitro fertilization cycles predict the risk of ovarian hyperstimulation syndrome. Fertil. Steril. 1999;71:287–293
  3. Alon T, Hemo I, Itin A, Peer J, Stone J, Keshet E. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat. Med. 1995;1:1024–1028
  4. Artini PG, Monti M, Fasciani A, Tartaglia ML, D’Ambrogio G, Genazzani AR. Correlation between the amount of follicle-stimulating hormone administered and plasma and follicular fluid vascular endothelial growth factor concentrations undergoing in vitro fertilization. Gynecol. Endocrinol. 1998;12:243–247
  5. Artini PG, Fasciani A, Monti M, Luisi S, D’Ambrogio G, Genazzani AR. Changes in vascular endothelial growth factor levels and the risk of ovarian hyperstimulation syndrome in women enrolled in an in vitro fertilization program. Fertil. Steril. 1998;70:560–564
  6. Balasch J, Reverter JC, Fabregues F, Tassies D, Ordinas A, Vanrell JA. Increased induced monocyte tissue factor expression by plasma from patients with severe ovarian hyperstimulation syndrome. Fertil. Steril. 1996;66:608–613
  7. Boesiger J, Tsai M, Maurer M, Yamaguchi M, Brown LF, Claffey KP, et al. Mast cells can secrete vascular permeability factor/vascular endothelial cell growth factor and exhibit enhanced release after immunoglobulin E-dependent upregulation of fc epsilon receptor I expression. J. Exp. Med. 1998;188:1135–1145
  8. Brännström M, Pascoe V, Norman RJ, McClure N. Localization of leukocyte subsets in the follicle wall and in the corpus luteum throughout the human menstrual cycle. Fertil. Steril. 1994;61:488–495
  9. Cohen T, Nahari D, Cerem LW, Neufeld G, Levi BZ. Interleukin-6 induces the expression of vascular endothelial growth factor. J. Biol. Chem. 1996;271:736–741
  10. de Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N, Williams LT. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science. 1992;255:989–991
  11. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am. J. Pathol. 1995;146:1029–1039
  12. Editorial, Ovarian hyperstimulation syndrome. Lancet 1991;338:1111–2.
  13. Elchalal U, Schenker JG. The pathophysiology of ovarian hyperstimulation syndrome — views and ideas [see comments]. Hum. Reprod. 1997;12:1129–1137
  14. Enskog A, Henriksson M, Unander M, Nilsson L, Brännström M. Prospective study of the clinical and laboratory parameters of patients in whom ovarian hyperstimulation syndrome developed during controlled ovarian hyperstimulation for in vitro fertilization. Fertil. Steril. 1999;71:808–814
  15. Fabregues F, Balasch J, Manau D, Jimenez W, Arroyo V, Creus M, et al. Haematocrit, leukocyte and platelet counts and the severity of the ovarian hyperstimulation syndrome. Hum. Reprod. 1998;13:2406–2410
  16. Ferrara N. Role of vascular endothelial growth factor in the regulation of angiogenesis. Kidney Int. 1999;56:794–814
  17. Freeman MR, Schneck FX, Gagnon ML, Corless C, Soker S, Niknejad K, et al. Peripheral blood T-lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor: a potential role for T-cells in angiogenesis. Cancer Res. 1995;55:4140–4145
  18. Friedlander MA, Loret de Mola JR, Goldfarb JM. Elevated levels of interleukin-6 in ascites and serum from women with ovarian hyperstimulation syndrome. Fertil. Steril. 1993;60:826–833
  19. Gaudry M, Bregerie O, Andrieu V, El Benna J, Pocidalo MA, Hakim J. Intracellular pool of vascular endothelial growth factor in human neutrophils. Blood. 1997;90:4153–4161
  20. Huang S, Xie K, Bucana CD, Ullrich SE, Bar-Eli M. Interleukin-10 suppresses tumor growth and metastasis of human melanoma cells: potential inhibition of angiogenesis. Clin. Cancer Res. 1996;2:1969–1979
  21. Iruela-Arispe ML, Lombardo M, Krutzsch HC, Lawler J, Roberts DD. Inhibition of angiogenesis by thrombospondin-1 is mediated by 2 independent regions within the type 1 repeats. Circulation. 1999;100:1423–1431
  22. Ishibashi T, Kimura H, Shikama Y, Uchida T, Kariyone S, Hirano T, et al. Interleukin-6 is a potent thrombopoietic factor in vivo in mice. Blood. 1989;74:1241–1244
  23. Kaipainen A, Korhonen J, Mustonen T, van Hinsbergh VW, Fang GH, Dumont D, et al. Expression of the fms-like tyrosine kinase-4 gene becomes restricted to lymphatic endothelium during development. Proc. Natl. Acad. Sci. U. S. A. 1995;92:3566–3570
  24. Keck C, Rajabi Z, Pfeifer K, Bettendorf H, Brandstetter T, Breckwoldt M. Expression of interleukin-6 and interleukin-6 receptors in human granulosa lutein cells. Mol. Hum. Reprod. 1998;4:1071–1076
  25. Keck PJ, Hauser SD, Krivi G, Sanzo K, Warren T, Feder J, et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science. 1989;246:1309–1312
  26. Krasnow JS, Berga SL, Guzick DS, Zelenik AJ, Yeo KT. Vascular permeability factor and vascular endothelial growth factor in ovarian hyperstimulation syndrome: a preliminary report. Fertil. Steril. 1996;65:552–555
  27. Lee A, Christenson LK, Stouffer RL, Burry KA, Patton PE. Vascular endothelial growth factor levels in serum and follicular fluid of patients undergoing in vitro fertilization.. Fertil. Steril. 1997;68:305–311
  28. Licht P, Engel N, Fischer O. HCG does not directly regulate circulating concentrations of vascular endothelial growth factor in IVF and embryo transfer cycles. Hum. Reprod. (abstract book). 1997;12:6
  29. Ludwig M, Jelkmann W, Bauer O, Diedrich K. Prediction of severe ovarian hyperstimulation syndrome by free serum vascular endothelial growth factor concentration on the day of human chorionic gonadotrophin administration. Hum. Reprod. 1999;14:2437–2441
  30. Lyons CA, Wheeler CA, Frishman GN, Hackett RJ, Seifer DB, Haning RV. Early and late presentation of the ovarian hyperstimulation syndrome: two distinct entities with different risk factors. Hum. Reprod. 1994;9:792–799
  31. Matsumoto K, Ohi H, Kanmatsuse K. Interleukin-4 cooperates with interleukin-10 to inhibit vascular permeability factor release by peripheral blood mononuclear cells from patients with minimal-change nephrotic syndrome. Am. J. Nephrol. 1999;19:21–27
  32. McClure N, Healy DL, Rogers PA, Sullivan J, Beaton L, Haning RV, et al. Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndrome. Lancet. 1994;344:235–236
  33. Mohle R, Green D, Moore MA, Nachman RL, Rafii S. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc. Natl. Acad. Sci. U. S. A. 1997;94:663–668
  34. Navot D, Bergh PA, Laufer N. The ovarian hyperstimulation syndrome. Reproductive Endocrinology, Surgery and Technology, Lippincott-Raven. Philadelphia. 1995;2:2215–2232
  35. Navot D, Relou A, Birkenfeld A, Rabinowitz R, Brzezinski A, Margalioth E. Risk factors and prognostic variables in the ovarian hyperstimulation syndrome. Am. J. Obstet. Gynecol. 1988;159:210–215
  36. Neulen J, Raczek S, Pogorzelski M, Grunwald K, Yeo TK, Dvorak HF, et al. Secretion of vascular endothelial growth factor/vascular permeability factor from human luteinized granulosa cells is human chorionic gonadotrophin dependent. Mol. Hum. Reprod. 1998;4:203–206
  37. Salven P, Orpana A, Joensuu H. Leukocytes and platelets of patients with cancer contain high levels of vascular endothelial growth factor. Clin. Cancer Res. 1999;5:487–491
  38. Terman BI, Dougher-Vermazen M, Carrion ME, Dimitrov D, Armellino DC, Gospodarowicz D, et al. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem. Biophys. Res. Commun. 1992;187:1579–1586
  39. Verheul HM, Hoekman K, Luykx-de Bakker S, Eekman CA, Folman CC, Broxterman HJ, et al. Platelet: transporter of vascular endothelial growth factor. Clin. Cancer Res. 1997;3:2187–2190
  40. Yan Z, Weich HA, Bernart W, Breckwoldt M, Neulen J. Vascular endothelial growth factor (VEGF) messenger ribonucleic acid (mRNA) expression in luteinized human granulosa cells in vitro. J. Clin. Endocrinol. Metab. 1993;77:1723–1725

PII: S0301-2115(00)00460-7

European Journal of Obstetrics & Gynecology and Reproductive Biology
Volume 96, Issue 2 , Pages 196-201 , June 2001

Article Tools

* Image Usage & Resolution